VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market

New Post Public Reply Private Reply Replies (0) Message Board
louied91
93
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus

https://thestreetreports.com/vivosim-labs-nas...-in-focus/

August 14, 2026 VivoSim Labs, Inc. (NASDAQ: VIVS) is emerging at the intersection of artificial intelligence, biotechnology, drug development, 3D human tissue models and New Approach Methodologies (NAMs) as pharmaceutical companies face increasing pressure to identify costly drug toxicity problems earlier in the development process.

While VivoSim is commonly characterized as a developer of 3D human liver and intestinal tissue models, its broader commercial opportunity may be more significant: helping pharmaceutical and biotechnology companies determine which drug candidates warrant additional development capital before expensive clinical trials begin.

That potential is becoming increasingly relevant as the U.S. Food and Drug Administration (FDA) advances policies encouraging human-relevant alternatives to traditional animal testing.

In March 2026, the FDA issued draft guidance establishing a validation framework for New Approach Methodologies in drug development, specifically identifying approaches including organoids, spheroids, organs-on-chips, in-vitro models and computer-based methods. The FDA said NAMs can help identify toxicities, improve the predictivity of nonclinical studies and potentially enhance clinical-trial safety.

The regulatory momentum continued in May when the FDA issued additional draft guidance designed to reduce unnecessary animal testing for certain oncology drugs, including biologics and conjugated products.

For investors following VIVS stock, biotech stocks, AI drug discovery, pharmaceutical research, preclinical drug testing, organ-on-chip technology and alternatives to animal testing, the evolving regulatory landscape places VivoSim’s technology in an increasingly relevant market. Other actively traded stocks under $1 drawing investor attention include SurgePays, Inc. (NASDAQ: SURG), IGC Pharma, Inc. (NYSE: IGC), Mangoceuticals, Inc. (NASDAQ: MGRX), Kartoon Studios, Inc. (NYSE: TOON), MDxHealth SA (NASDAQ: MDXH), Peraso Inc. (NASDAQ: PRSO) Cycurion, Inc. (NASDAQ: CYCU) and Algorhythm Inc (NASDAQ: RIME) as traders continue to monitor micro-cap and small-cap stocks for developing news, volume and market activity.

VivoSim Reports 91% Predictive Accuracy in Liver Toxicity Testing

A key component of VivoSim’s investment story is whether its human tissue models can provide actionable information about drug toxicity.

In June, VivoSim reported results from a 92-compound clinical small-molecule dataset evaluating its NAMkind™ Liver spheroid technology. According to the company, its repeat-dose testing achieved 91% predictive accuracy, 90% sensitivity and 95% specificity.

The results are company-reported and require continued validation as VivoSim expands commercial adoption, but they point toward a potentially important application: identifying compounds carrying liver toxicity risks before substantially more capital is committed to clinical development.

Rather than simply selling a laboratory model, VivoSim is positioning NAMkind as a potential drug-development decision-support platform.

AI-Powered Gastrointestinal Toxicity Prediction Expands the Opportunity

VivoSim is also extending the platform beyond liver toxicity.

In April, the company reported that its VitroSense™ AI system, trained using data generated by NAMkind human intestinal models, achieved 96% predictive accuracy in its training dataset for potential drug-induced diarrhea.

This combination of artificial intelligence and human 3D tissue models could expand VivoSim’s addressable market by transforming biological testing data into predictive information pharmaceutical researchers can use when evaluating drug candidates.

The strategy aligns with the FDA’s broader movement toward advanced, human-relevant drug safety methods, which includes both sophisticated in-vitro models and computational approaches.

Antibody-Drug Conjugates Open Another Potential Market

VivoSim is also targeting the rapidly developing antibody-drug conjugate (ADC) sector.

The company reported in March that its NAMkind liver and intestinal models demonstrated an ability to distinguish toxicity associated with different ADC components, including antibodies, payloads and linker chemistry.

The timing could prove important. The FDA’s May 2026 draft oncology guidance specifically addresses streamlined nonclinical safety assessment for certain biologics and conjugated products, providing a regulatory backdrop relevant to VivoSim’s ADC testing strategy.

Commercialization Begins as VivoSim Enters China

The next phase for VivoSim is increasingly about commercial execution rather than scientific validation alone.

In July, VivoSim announced its first commercial sales of NAMkind toxicology screening and efficacy-testing services in mainland China, representing an early step toward converting its technology into recurring pharmaceutical research revenue. The company’s investor-relations site lists the China commercial launch among its recent operating milestones.

Investors will now be watching for additional pharmaceutical customers, repeat studies, larger contracts and evidence that NAMkind-generated data are being incorporated into actual drug-development decisions.

$5 Million Eli Lilly Payment and 500%+ FY2027 Revenue Growth Guidance

VivoSim’s financial position has also gained attention.

The company received a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) following dosing of the first patient in a Phase 2 study involving an inflammatory bowel disease program previously sold to Lilly. VivoSim has stated that it remains eligible for up to an additional $45 million in potential milestone payments if specified regulatory and commercial milestones are achieved.

Importantly, the Lilly milestone should not be confused with NAMkind commercial revenue. However, it provides VivoSim with additional capital while the company works to expand its contract research business.

VivoSim has separately reiterated expectations for more than 500% revenue growth in fiscal 2027, citing progress marketing NAM-based contract research services to pharmaceutical companies.

The company recently reported approximately $10.1 million in cash as of August 3, 2026, following the Lilly milestone payment, release of additional escrowed funds associated with the earlier FXR transaction and proceeds from a July financing.

The Bigger VivoSim Investment Thesis: Predict Drug Failure Earlier

The developing VivoSim story may ultimately be less about 3D tissue models themselves and more about the economic value of predicting drug toxicity earlier.

Drug development is expensive, lengthy and characterized by substantial clinical failure risk. Technology capable of identifying toxicity problems before companies commit additional capital to clinical trials could therefore carry strategic value beyond traditional laboratory research services.

VivoSim’s NAMkind technology is the underlying platform. Liver toxicity, gastrointestinal toxicity and ADC safety testing represent initial commercial applications. Artificial intelligence may further increase the usefulness of the resulting biological data.

The potential business model is therefore straightforward: provide pharmaceutical companies with better human-relevant information earlier, when they still have an opportunity to modify a compound, adjust development strategy or discontinue a program before significantly more capital is deployed.

That thesis remains to be proven commercially. VivoSim must demonstrate repeat pharmaceutical adoption, increasing contract research revenue, continued predictive performance and an ability to execute against its aggressive 500%+ FY2027 revenue-growth guidance.

But the market backdrop is changing at the same time VivoSim is attempting to commercialize its platform. The FDA is actively establishing a framework for NAMs and human-relevant drug testing, VivoSim has begun generating commercial NAMkind business, and management is forecasting substantial revenue expansion.

For investors searching for VIVS stock, biotech stocks under $1, AI biotechnology stocks, New Approach Methodologies, FDA animal testing alternatives, 3D human tissue models, drug toxicity testing, antibody-drug conjugates, pharmaceutical contract research and AI drug development, VivoSim Labs represents an emerging company to watch as the pharmaceutical industry moves toward more predictive, human-relevant preclinical testing.

About VivoSim Labs, Inc.

VivoSim Labs, Inc. (NASDAQ: VIVS) provides pharmaceutical and biotechnology companies with 3D human liver and intestinal tissue models for drug testing and toxicology using New Approach Methodologies (NAMs). VivoSim’s technologies are designed to provide human-relevant information that can assist drug developers in evaluating toxicity and potential safety risks during preclinical development.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 27

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 33

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 278

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 14

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 147

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 202

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 86

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 16

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 114

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 80

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading

Top 5 Most Recently Viewed Articles

Vancity Achieves Remarkable Q2 Performance Amid Strategic Shift

Updated Category News Views 345

Vancity Reports Strong Financial Performance in Q2 Vancity recently showcased its outstanding financial results for the second quarter, demonstrating impressive growth across various metrics and solidifying its commitment to its members. This performance is part of Vancity's transformative vision to enhance member experience while making significant contributions to local...

Continue Reading
Celebrating Courtney Rollings Latham's Exceptional Contributions

Updated Category News Views 283

Honoring Courtney Rollings Latham, M.Ed, BCBA It brings us great joy to acknowledge Courtney Rollings Latham, M.Ed, BCBA, for achieving the status of a Pinnacle Professional Member in The Inner Circle of Excellence. This recognition showcases her steadfast commitment to enhancing the fields of Behavior Analysis and Special Education. A Passionate Educator and Analyst...

Continue Reading
Savers Value Village, Inc. Reveals Sales Growth and Conference Plans

Updated Category News Views 158

Savers Value Village, Inc. Reports Preliminary Sales Results BELLEVUE, Wash. – Savers Value Village, Inc. (NYSE: SVV) has released its preliminary net sales for the recent quarter along with its full year results for fiscal 2024. This announcement coincides with the Company’s upcoming participation in the ICR Conference scheduled for mid-January 2025. Sales...

Continue Reading
Empowering Salon Professionals Through Natural Disasters Support

Updated Category News Views 241

Empowering Professionals in the Face of Adversity Natural disasters can strike unexpectedly, causing chaos and distress. My Salon Suite®, a franchise dedicated to providing beauty, health, and wellness professionals with personal spaces for their businesses, has been at the forefront of community support during such challenging times. As we navigate through the hurricane...

Continue Reading
Major Revenue Surge: POP Culture Group's Impressive FY2025 Results

Updated Category News Views 201

POP Culture Group Achieves Record Revenue in FY2025 In a remarkable financial breakthrough, POP Culture Group Co., Ltd. (Nasdaq: CPOP) has announced its fiscal year 2025 results, showcasing an incredible revenue surge that exceeded $100 million for the first time. This milestone represents a significant leap, with revenue increasing by 127% compared to the previous fiscal...

Continue Reading